A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. - Wikidata - wikimedia - TriplyDB

A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk.

A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk.

http://www.wikidata.org/entity/Q34402606

about

Anticoagulation Management and Monitoring during Pediatric Extracorporeal Life Support: A Review of Current Issues Venovenous Extracorporeal Membrane Oxygenation in Intractable Pulmonary Insufficiency: Practical Issues and Future Directions The factor XIIa blocking antibody 3F7: a safe anticoagulant with anti-inflammatory activities Future prospects for contact factors as therapeutic targets Factor XI and contact activation as targets for antithrombotic therapy The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology A Novel Antithrombotic Mechanism Mediated by the Receptors of the Kallikrein/Kinin and Renin-Angiotensin Systems Coagulation factor XII protease domain crystal structure.Factor XII as a Risk Marker for Hemorrhagic Stroke: A Prospective Cohort Study.Anticoagulation Therapy during Extracorporeal Membrane Oxygenator Support in Pediatric Patients.Thrombosis Prevention without Anticoagulation.Activation of the factor XII-driven contact system in Alzheimer's disease patient and mouse model plasma.Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoprotein Safe anticoagulation when heart and lungs are "on vacation".Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III The hypercoagulable profile of patients with stent thrombosis.The Coagulation Factor XIIa Inhibitor rHA-Infestin-4 Improves Outcome after Cerebral Ischemia/Reperfusion Injury in Rats The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis.A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation.How it all starts: Initiation of the clotting cascade.The Alzheimer's disease peptide β-amyloid promotes thrombin generation through activation of coagulation factor XII.Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection.Factors XI and XII as Targets for New Anticoagulants.Update on the role of extracorporeal CO₂ removal as an adjunct to mechanical ventilation in ARDS.Antithrombotic therapy for ventricular assist devices in children: do we really know what to do?Medical device-induced thrombosis: what causes it and how can we prevent it?Factor XII: a novel target for safe prevention of thrombosis and inflammation.The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities.Assessment of the protein interaction between coagulation factor XII and corn trypsin inhibitor by molecular docking and biochemical validation Prothrombotic aspects of sickle cell disease.A flow cytometry-based assay for procoagulant platelet polyphosphate.The Story of Angioedema: from Quincke to Bradykinin.Factor XII: form determines function.Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS).Antithrombotic potential of the contact activation pathway.Upstream versus downstream thrombin inhibition.The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.Cardiovascular disease in haemodialysis: role of the intravascular innate immune system.Single-chain factor XII: a new form of activated factor XII.FXIIa inhibitor rHA-Infestin-4: Safe thromboprotection in experimental venous, arterial and foreign surface-induced thrombosis.

P2860

Q26742088-91FF2192-0F0A-46E9-972E-12CF634681DD Q26748920-D88EC049-9E40-4735-92D2-D04554C1F9FD Q26775616-CAAF8DFE-7843-4E21-AC1E-669C512504FD Q26865096-A19D9B03-5679-452A-9203-95A36A300EC3 Q27024190-BA4F317C-B8FF-41E6-8E93-E0A29EF1DE92 Q28068216-8C52B822-A6CB-4818-B958-C15A7CAA0619 Q28069799-EEA92961-36D9-41CC-87FE-ECA663B43BB5 Q30370920-A65855AF-C345-4B0E-B7FA-5A2435B6D403 Q33706174-B3CD07DC-BC7E-4285-AD27-97A38B550732 Q33760799-A24ADFFD-EEAC-48E6-A15B-AFA5DD072B80 Q35104501-B7B6A2B3-EB46-4048-AE26-ED7EB31082B1 Q35279729-11206A9E-9CB1-4996-B10D-91AD8C732627 Q35561296-8C671AB8-6E98-470E-9E01-5C5F83E0A805 Q35625209-4DEF3663-8AC3-49EC-A8F5-CC2F242ADB62 Q35700453-9C6B47F2-0FB8-4159-B164-7A5B3DA6FD78 Q35891856-0D238655-997E-499D-8AF8-A524FA973BC9 Q35905607-477370B6-9600-4C1D-A313-79F19FDC25E9 Q36051099-B4DDD940-F60D-4717-9904-359E095B22F2 Q36767718-B4B070BF-49D1-4791-BE3C-F33F9BB06565 Q36783613-31CA20EB-6804-47B2-BEED-11054D956543 Q36909451-221461B8-2214-44B6-9D3D-42A1F438AA53 Q37261059-DFBE13A1-0C1E-4CEA-B003-AA8113A89575 Q37662547-9E1EC7F9-0E22-46E9-B02A-5650CDD2C5CC Q38427370-71E58284-647B-4774-90BA-E913007E3086 Q38543315-F6490EB4-36D6-42A5-97FE-DC23310FB509 Q38543320-69D453D3-9EE1-40BA-B01D-9CBFBEB797D6 Q38587540-02D9D545-A42E-4DC6-9297-3B20C6DC45D2 Q38632499-C5D61054-C744-4EC8-AC6A-C65B284A8B6D Q38688610-2AF3C592-B571-409F-889B-D5BFBBC873CF Q38696998-981F67FC-E534-4D3E-B987-22C9A13550C3 Q38798595-844B6863-E079-41A7-ABF7-AED7888B5662 Q38855032-330D255B-5142-4278-A693-420EC963F9A9 Q38860396-7729D67E-EC4E-4053-A32A-601FA9DDCDB6 Q38865628-A8F16D5F-B11C-453C-A3EE-A14C2D9CC80C Q38886826-14B2B3DB-2F03-4794-AC74-B4506971CAB5 Q38941069-42D65386-B579-429C-9617-9DAE145E00AA Q38956551-9D3197D9-FBC6-40F0-8F5C-88D1095C34C5 Q39151839-BBCA05EA-692F-4FBD-BE50-CDEB1C3CAC22 Q39366435-2FFB1191-F7CA-4DF0-A403-6EDECA8EAE75 Q39886396-2EA2F301-2B9C-42FD-81A8-32FB618E14EB

P2860

A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk.

http://www.wikidata.org/entity/Q34402606

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A factor XIIa inhibitory antib ...... hout increasing bleeding risk.

@ast

A factor XIIa inhibitory antib ...... hout increasing bleeding risk.

@en

A factor XIIa inhibitory antib ...... hout increasing bleeding risk.

@nl

type

label

A factor XIIa inhibitory antib ...... hout increasing bleeding risk.

@ast

A factor XIIa inhibitory antib ...... hout increasing bleeding risk.

@en

A factor XIIa inhibitory antib ...... hout increasing bleeding risk.

@nl

prefLabel

A factor XIIa inhibitory antib ...... hout increasing bleeding risk.

@ast

A factor XIIa inhibitory antib ...... hout increasing bleeding risk.

@en

A factor XIIa inhibitory antib ...... hout increasing bleeding risk.

@nl

P1433

Q34402606-FC4697E1-E309-4BA8-9856-BCE931BC44FB

P1476

Q34402606-596237CC-DB92-46E8-A587-AC5789A63A5B

P2093

Q34402606-2E7E5A86-1031-40C4-8B4D-57B92A642CA1

Q34402606-3C67A2EB-FC7D-4121-BA63-4E65618014BF

Q34402606-47F2DE55-02B4-4141-B486-64203621936C

Q34402606-72BAF4CA-08A8-4A58-B7CF-9DC719C91DD6

Q34402606-7FDC60E2-DCA3-4CB2-B025-C0DE727F16BB

Q34402606-95451D8C-0EBF-4D0D-8432-F24F5D94F65E

Q34402606-A3E2C38B-70DD-4BFE-9D25-2FA9A8A6462A

Q34402606-A6142C6A-8D03-465A-864F-8497FA0C6DB5

Q34402606-C0439282-CDC7-431F-A92C-168F40E8DDD9

Q34402606-C6E2C188-0C30-4068-80FE-FE34F815743B

P2860

Q34402606-01CDFBFC-A982-49FD-BBDB-704C220A0020

Q34402606-093AD3C5-B4A6-4929-A06A-86FB1E61F845

Q34402606-0AD50901-6039-4FBD-9EBC-04EE1FAA577D

Q34402606-1E65A9EE-16E7-40EF-9F5E-9BFA241F2292

Q34402606-1EC7C63F-0E24-4ED2-AEAF-3A2B12E80BCE

Q34402606-232A838A-3D93-470E-BF3E-EA89FCACB4B0

Q34402606-25A8370C-7B7F-4DC1-9E04-E8D4191E8340

Q34402606-2BD21F45-5173-4D0B-A456-5FA1C5D8B48B

Q34402606-3F89988B-DB8A-4EE3-9CBE-ECC67933B36E

Q34402606-5102051A-EA35-4D10-BA49-ED0E37D9B28D

P304

Q34402606-59068B69-8ACA-48A1-9CB6-7846DDCBD741

P31

Q34402606-58D9FB52-283A-40B1-A388-FA9FA62B26F9

P356

Q34402606-59A132CD-6124-4E57-8A0D-504046CD4F5E

P407

Q34402606-DE618F65-0752-46D2-A6A5-45E986412824

P433

Q34402606-C297AB5A-8E57-47EB-9DBC-ED4A0AB94164

P478

Q34402606-5AF07C0C-0E9E-42B8-8FBF-A0A3C5BA054D

P50

Q34402606-4F345371-0005-4954-8091-0A8495020D49

Q34402606-F07C1E73-71FD-4813-B871-A97861D855B0

P577

Q34402606-188E2958-1B8E-446B-955E-6179708462F3

P698

Q34402606-216F7D8A-7BAD-4D17-9DF7-0855CA02C01C

P921

Q34402606-A91CA9B0-704A-4B7A-A679-586B04D88105

P356

SCITRANSLMED.3006804

P1433

Science Translational Medicine

P1476

A factor XIIa inhibitory antib ...... thout increasing bleeding risk

@en

P2093

Andrew D Nash

http://www.w3.org/2001/XMLSchema#string

Anne Jämsä

http://www.w3.org/2001/XMLSchema#string

Con Panousis

http://www.w3.org/2001/XMLSchema#string

Gerhard Dickneite

http://www.w3.org/2001/XMLSchema#string

Ingo Pragst

http://www.w3.org/2001/XMLSchema#string

Katrin F Nickel

http://www.w3.org/2001/XMLSchema#string

Magnus Larsson

http://www.w3.org/2001/XMLSchema#string

Marc W Nolte

http://www.w3.org/2001/XMLSchema#string

Marion Fries

http://www.w3.org/2001/XMLSchema#string

Matthew P Hardy

http://www.w3.org/2001/XMLSchema#string

P2860

Defective thrombus formation in mice lacking coagulation factor XII

Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo

International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences

Role of tissue factor in hemostasis, thrombosis, and vascular development

Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis

A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo

Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries.

A new phosphorylcholine-coated polymethylpentene oxygenator for extracorporeal membrane oxygenation: a preliminary experience.

Triggers, targets and treatments for thrombosis.

Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo.

P304

222ra17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3006804

http://www.w3.org/2001/XMLSchema#string

P407

P433

222

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Michael Broomé

Jenny Björkqvist

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24500405

http://www.w3.org/2001/XMLSchema#string

P921